Comparison of the effects of potential parenteral vehicles for poorly water soluble anticancer drugs (organic cosolvents and cyclodextrin solutions) on cultured endothelial cells (HUV-EC)

Journal of Pharmaceutical Sciences

Volumn 87, Issue 9, 1998, Pages 1138-1143

  Medlicott, Natalie J ^a,c   Foster, Kimberly A ^a   Audus, Kenneth L ^a   Gupta, Shanker ^b   Stella, Valentino J ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLODEXTRIN; DRUG SOLVENT; LACTATE DEHYDROGENASE; MELPHALAN;

ARTICLE; CELL CULTURE; CELL VIABILITY; DRUG EFFECT; DRUG FORMULATION; DRUG SOLUBILITY; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PHASE CONTRAST MICROSCOPY; UMBILICAL VEIN;

EID: 0031657040     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js9704442     Document Type: Article

References (24)

1. Banerjee, A.; Brotherston, T. M.; Lamberty, B. G. H.; Campbell, R. C. Cancer chemotherapy agent-induced perivasation injuries. Postgrad. Med. J. 1987, 63, 5-9.
2. Reed, K. W.; Yalkowsky, S. H. Lysis of human red blood cells in the presence of various cosolvents. J. Parenter. Sci. Technol. 1985, 39, 64-68.
3. Reed, K.; Yalkowsky, S. H. Lysis of human red blood cells in the presence of various cosolvents II. The effect of differing NaCl concentrations. J. Parenter. Sci. Technol. 1986, 40, 88-94.
4. Reed, K. W.; Yalkowsky, S. H. Lysis of human red blood cells in the presence of various cosolvents. III. The relationship between hemolytic potential and structure. J. Parenter. Sci. Technol., 1987, 41, 37-39.
5. Brazeau, G. A.; Fung, H. L. An in vitro model to evaluate muscle damage following intramuscular injections. Pharm. Res., 1989, 6, 167-170.
6. Brazeau, G. A.; Fung, H. L. Use of an in vitro model for the assessment of muscle damage from intramuscular injections. Pharm Res, 1989, 6, 766-771.
7. Laska, D.; Williams, P.; Reboulet, J.; Morris, R. The L6 muscle cell line as a tool to evaluate parenteral products for irritation. J. Parenter. Sci. Technol., 1991, 45, 77-82.
8. Evans, L. A.; Genereux, P. E.; Gibbs, M.; Sutton, S. Predicting injection site muscle damage III: Evaluation of intramuscular formulations in the L6 cell model. Pharm. Res., 1996, 13, 1585-1587.
9. Rajewski, R. A.; Stella, V. J. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J. Pharm. Sci., 1996, 85, 1142-1169.
10. Gupta, S. L.; Patel, J. P.; Jones, D. L.; Partipilo, R. W. Parenteral formulation development of renin inhibitor Abbott-72517. J. Pharm. Sci. Technol., 1994, 48, 86-91.
11. Fu, R. C.; Lidgate, D. M.; Whatley, J. L.; McCullough, T. The biocompatibility of parenteral vehicles - in vitro/in vivo screening comparison and the effect of excipients on hemolysis. J. Parenter. Sci. Technol., 1987, 41, 164-168.
12. Leroy-Lechat, F.; Wouessidjewe, D.; Andreux, J.-P.; Puisieux, F.; Duchene, D. Evaluation of the cytotoxicity of cyclodextrins and hydroxypropylated derivatives. Int. J. Pharm., 1994, 101, 97-103.
13. Yoshida, A.; Arima, H.; Uekama, K.; Pitha, J. Pharmaceutical evaluation of hydroxyalkyl ethers of β-cyclodextrin. Int. J. Pharm., 1988, 46, 217-222.
14. Rajewski, R. A.; Traiger, G.; Bresnahan, J.; Jaberaboansari, P.; Stella, V. J.; Thompson, D. O. Preliminary safety evaluation of parenterally administered sulfoalkyl ether β-cyclodextrin derivatives. J. Pharm. Sci., 1995, 84, 927-932.
15. Shiotani, K.; Uehata, K.; Irie, T.; Uekama, K.; Thompson, D. O.; Stella, V. J. Differential effects of sulfate and sulfobutyl ether of β-cyclodextrin on erythrocyte membranes in vitro. Pharm. Res., 1995, 12, 78-84.
16. McEvoy, G. K., Ed. American Hospital Formulary Service. Drug Information; American Society of Health-System Pharmacists, Inc.: Bethesda, MD, 1996.
17. Lutz, K. L.; Siahaan, T. J. Molecular structure of the apical junction complex and its contribution to the paracellular barrier. J. Pharm. Sci., 1997, 86, 977-984.
18. Freshney, R. I. Culture of Animal Cells, 3rd ed.; Wiley-Liss Inc.: New York, 1994.
19. Grant, R. L.; Yao, C.; Gabaldon, D.; Acosta, D. Evaluation of surfactant cytotoxicity potential by primary cultures of ocular tissues: I. Characterization of rabbit corneal epithelial cells and initial injury and delayed toxicity studies. Toxicology, 1992, 76, 153-176.
20. Brazeau, G. A.; Watts, S. S.; Mathews, L. S. Role of calcium and arachidonic acid metabolites in creatine kinase release from isolated rat skeletal muscles damaged by organic cosolvent. J. Parenter. Sci. Technol., 1992, 46, 25-30.
21. Brazeau, G. A.; Fung, H. L. Mechanisms of creatine kinase release from isolated rat skeletal muscles damaged by propylene glycol and ethanol. J. Pharm. Sci., 1990, 79, 393-397.
22. Grant, R. L.; Acosta, D. Comparative toxicity of tetracaine, proparacaine and cocaine evaluated with primary cultures of rabbit corneal epithelial cells. Exp. Eye Res., 1994, 58, 469-478.
23. Irie, T.; Uekama, K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues ans safety evaluation. J. Pharm. Sci., 1997, 86, 147-162.
24. Shao, Z.; Krishnamoorthy, R.; Mitra, A. K. Cyclodextrins as nasal absorption promoters of insulin: mechanistic evaluations. Pharm. Res., 1992, 9, 1157-1163.